PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.30%
Negative revenue growth while MRVL stands at 4.29%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-4.22%
Negative gross profit growth while MRVL is at 3.82%. Joel Greenblatt would examine cost competitiveness or demand decline.
15.97%
EBIT growth above 1.5x MRVL's 8.09%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
15.09%
Operating income growth similar to MRVL's 15.99%. Walter Schloss would assume both share comparable operational structures.
-6.77%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-2.56%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-2.63%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.73%
Slight or no buybacks while MRVL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
17.08%
Diluted share count expanding well above MRVL's 1.17%. Michael Burry would fear significant dilution to existing owners' stakes.
4.95%
Maintaining or increasing dividends while MRVL cut them. John Neff might see a strong edge in shareholder returns.
34.22%
Positive OCF growth while MRVL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
-197.20%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
29.76%
10Y revenue/share CAGR at 50-75% of MRVL's 56.20%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
-26.65%
Negative 5Y CAGR while MRVL stands at 109.65%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
12.01%
3Y revenue/share CAGR under 50% of MRVL's 25.49%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-2.10%
Negative 10Y OCF/share CAGR while MRVL stands at 237.57%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
7.60%
Below 50% of MRVL's 45.44%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
24.27%
3Y OCF/share CAGR under 50% of MRVL's 63.72%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
953.20%
Net income/share CAGR 1.25-1.5x MRVL's 653.69%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
90.10%
Below 50% of MRVL's 220.76%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
299.75%
3Y net income/share CAGR 1.25-1.5x MRVL's 202.86%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
302.95%
10Y equity/share CAGR above 1.5x MRVL's 54.87%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
168.64%
5Y equity/share CAGR above 1.5x MRVL's 19.67%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
91.42%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
21.42%
10Y dividend/share CAGR above 1.5x MRVL's 0.04%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
-2.02%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-2.13%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-6.69%
Firm’s AR is declining while MRVL shows 11.24%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
9.89%
Inventory growth well above MRVL's 4.05%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-3.38%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
0.45%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
-3.74%
We’re deleveraging while MRVL stands at 3.89%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-17.26%
Our R&D shrinks while MRVL invests at 1.74%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-11.48%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.